finance.yahoo.com ·
Rocket Pharmaceuticals Rckt Reports Q1
Topic context
This topic has been covered 294822 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRocket Pharmaceuticals is a biotech company with no approved products generating revenue; the $180 million voucher sale provides non-dilutive funding but does not create a commercial mechanism for any sector beyond the company's own pipeline. The impact is single-company-specific with no direct commodity, supply chain, or margin effect on broader markets. The company's cash runway is extended, but no product revenue or cost pass-through is evident.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 net loss of $47.6 million, or $0.42 per share
- R&D expenses $31.5 million, G&A expenses $17.1 million
- Cash $144.4 million at quarter end, pro forma $322.6 million after $180 million Priority Review Voucher sale
- FDA accelerated approval of KRESLADI for pediatric LAD-I
- Phase 2 trial of RP-A501 for Danon disease reinitiated; Phase 2 trial for RP-A601 in arrhythmogenic cardiomyopathy in alignment with FDA; first-patient dosing for Phase 1 BAG3-dilated cardiomyopathy study expected mid-2026
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
economictimes.indiatimes.com